Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Proteome SciencesCHIX:PRML Days Sales Outstanding is 58.91 as of Dec. 2025, which is 75% above its 10-year median of 33.60. The stock has 6 warning signs investors should review. Among 202 Medical Diagnostics & Research companies, Proteome Sciences ranks better than 75.74% on this metric.
The historical rank and industry rank for Proteome Sciences's Days Sales Outstanding or its related term are showing as below:
CHIX:PRMl'
s Days Sales Outstanding Range Over the Past 10 Years
Min: 20.07 Med: 33.6 Max: 62.18
Current: 46.61
During the past 13 years, Proteome Sciences's highest Days Sales Outstanding was 62.18. The lowest was 20.07. And the median was 33.60.
CHIX:PRMl's Days Sales Outstanding is ranked better than 75.74% of 202
companies
in the Medical Diagnostics & Research industry
Industry Median: 67.76
vs CHIX:PRMl: 46.61
Proteome Sciences's Days Sales Outstanding
increased
from Dec. 2024 (20.27) to Dec. 2025 (58.91).
Proteome Sciences (CHIX:PRMl) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Proteome Sciences Days Sales Outstanding Related Terms
Proteome Sciences Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Proteome Sciences's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PRML vs TMO, DHR, IDXX: Days Sales Outstanding Comparison
For the Diagnostics & Research subindustry, Proteome Sciences's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Proteome Sciences Days Sales Outstanding vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Proteome Sciences's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Proteome Sciences's Days Sales Outstanding falls into.
Proteome Sciences Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Proteome Sciences (CHIX:PRML) has a Days Sales Outstanding of 58.91 as of Dec. 2025. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Proteome Sciences and its competitors. This is 75% above median its historical median of 33.60. Over the past decade, Proteome Sciences' Days Sales Outstanding has ranged from 20.07 to 62.18. According to the industry distribution chart, Proteome Sciences ranks #49 out of 202 companies in the Medical Diagnostics & Research industry, placing it in the top 24.3%.
Is Proteome Sciences' Days Sales Outstanding too high?
Proteome Sciences' current Days Sales Outstanding of 58.91 is 75% above median its 10-year median of 33.60. Over the past 10 years, this metric has ranged from a low of 20.07 to a high of 62.18. The Medical Diagnostics & Research industry median Days Sales Outstanding is 67.76. Proteome Sciences' value of 58.91 is 13.1% below this industry median. Based on the distribution chart, Proteome Sciences ranks #49 out of 202 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers.
How does Proteome Sciences' Days Sales Outstanding compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Proteome Sciences ranks #49 out of 202 companies for Days Sales Outstanding. This places Proteome Sciences in the top 24% of its industry — outperforming the majority of peers. The industry median Days Sales Outstanding is 67.76. Proteome Sciences' value of 58.91 is 13.1% below this benchmark. Historically, Proteome Sciences' own Days Sales Outstanding has ranged from 20.07 to 62.18 over the past decade. While the company's 10-year median is 33.60 vs. the industry median of 67.76, Proteome Sciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Medical Diagnostics & Research company?
The median Days Sales Outstanding among Medical Diagnostics & Research companies is 67.76, based on 202 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Proteome Sciences's current Days Sales Outstanding of 58.91 is 13.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Proteome Sciences and its competitors. For the Medical Diagnostics & Research industry, the median Days Sales Outstanding is 67.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Proteome Sciences's current Days Sales Outstanding is 58.91, which is 75% above median its own 10-year median of 33.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Proteome Sciences stock overvalued right now?
Based on GuruFocus' analysis, Proteome Sciences (CHIX:PRML) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.02, compared to a current price of £0.02 — trading right at its estimated fair value. The current Days Sales Outstanding is 58.91, which is 75% above median its 10-year median of 33.60 and 13.1% below the Medical Diagnostics & Research industry median of 67.76. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Proteome Sciences (CHIX:PRML), the current Days Sales Outstanding is 58.91 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Proteome Sciences PLC is engaged in protein biomarker research and development. The company is a provider of contract research services for the identification, validation and application of protein biomarkers. The company's only reportable segment is the sale of goods and biomarker services. The company generates maximum revenue from the TMT product and end customer sales-based royalties. Geographically, it has a presence in the United States, the United Kingdom, the European Union, and Others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PRML has been successfully added to your 
